阿尔德脱酶2基因变异对肝细胞癌敏感性的诊断影响
Yu-Ting Chin1,2, Ming-Hsien Wu3,4, Hou-Yu Shih1,2
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
Cancer diagnosis & prognosis
|September 6, 2024
概括
阿尔代脱酶2 (ALDH2) rs671 AA基因型增加肝细胞癌 (HCC) 的风险,特别是在男性和非饮酒者中. 避免饮酒对于患有这种ALDH2基因型的人来说至关重要,以减轻HCC风险.
科学领域:
- 遗传学和基因组学 在
- 肝病学 肝病学是一种肝病学.
- 癌症研究 癌症研究
背景情况:
- 酒精消费,脱酶2 (ALDH2) 基因型和肝细胞癌 (HCC) 发展之间的相互作用需要进一步澄清.
- ALDH2在酒精代谢中起着至关重要的作用,影响个人对酒精相关疾病的易感性.
研究的目的:
- 调查ALDH2 rs671单核酸多态 (SNP) 和HCC风险之间的关联.
- 检查性和酒精消费如何改变ALDH2基因型和HCC发育之间的关系.
主要方法:
- 对ALDH2 rs671 SNP的基因定型在298名HCC患者和889名健康对照中进行.
- 使用后勤回归和基频率分析来评估关联,按性别和酒精消费分层.
主要成果:
- ALDH2 rs671 变异基因型显示,HCC 患者和对照人群之间的分布有显著差异 (p趋势=0.0311).
- 与野生类型的GG基因型相比,异合体AG和同合体AA基因型的携带者增加了HCC风险 (分别是1.22倍和1.77倍).
- 该A基因组与1.29倍增加的HCC风险相关 (p=0.0123). 值得注意的是,AA基因型携带者在男性和非酒精饮料者中具有显著更高的HCC风险.
结论:
- ALDH2基因型显著影响HCC风险,观察到与性和酒精消费的相互作用.
- 强烈建议ALDH2 rs671 AA基因型的个体避免饮酒,特别是男性,以减少患HCC的风险.
相关概念视频
01:27Principles of Pharmacogenetics: Types of Genetic Variants
138
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
138
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
159
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
338
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...
338
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
94
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
94
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121